Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 IPCA LABS   MYLAN
EQUITY SHARE DATA
    IPCA LABS
Mar-23
MYLAN
Dec-18
IPCA LABS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,0623,975-   
Low Rs7682,188-   
Sales per share (Unadj.) Rs243.01,829.1-  
Earnings per share (Unadj.) Rs19.449.7-  
Cash flow per share (Unadj.) Rs29.7392.1-  
Dividends per share (Unadj.) Rs4.000-  
Avg Dividend yield %0.40-  
Book value per share (Unadj.) Rs230.31,978.8-  
Shares outstanding (eoy) m253.70514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.81.7 223.5%   
Avg P/E ratio x47.262.0 76.1%  
P/CF ratio (eoy) x30.87.9 392.0%  
Price / Book Value ratio x4.01.6 255.1%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m232,1201,585,442 14.6%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m12,8760-   
Avg. sales/employee Rs Th026,887.8-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0730.1-  
INCOME DATA
Net Sales Rs m61,642941,074 6.6%  
Other income Rs m1,5180-   
Total revenues Rs m63,160941,074 6.7%   
Gross profit Rs m9,033243,515 3.7%  
Depreciation Rs m2,616176,206 1.5%   
Interest Rs m48245,262 1.1%   
Profit before tax Rs m7,45322,047 33.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,534-3,507 -72.2%   
Profit after tax Rs m4,91925,554 19.3%  
Gross profit margin %14.725.9 56.6%  
Effective tax rate %34.0-15.9 -213.7%   
Net profit margin %8.02.7 293.9%  
BALANCE SHEET DATA
Current assets Rs m51,893525,495 9.9%   
Current liabilities Rs m18,058383,144 4.7%   
Net working cap to sales %54.915.1 362.9%  
Current ratio x2.91.4 209.5%  
Inventory Days Days5184 61.3%  
Debtors Days Days693 6.3%  
Net fixed assets Rs m34,336182,553 18.8%   
Share capital Rs m254501 50.6%   
"Free" reserves Rs m58,1670-   
Net worth Rs m58,4201,018,070 5.7%   
Long term debt Rs m6,5181,098,825 0.6%   
Total assets Rs m86,2292,730,861 3.2%  
Interest coverage x16.51.5 1,107.2%   
Debt to equity ratio x0.11.1 10.3%  
Sales to assets ratio x0.70.3 207.4%   
Return on assets %6.32.6 241.5%  
Return on equity %8.42.5 335.5%  
Return on capital %12.23.2 384.3%  
Exports to sales %42.90-   
Imports to sales %13.30-   
Net fx Rs m18,2570-   
CASH FLOW
From Operations Rs m8,058195,555 4.1%  
From Investments Rs m-7,250-101,081 7.2%  
From Financial Activity Rs m5,072-91,101 -5.6%  
Net Cashflow Rs m5,8811,620 363.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.51 Rs / USD

Compare IPCA LABS With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare IPCA LABS With: NATCO PHARMA  ISHITA DRUGS  CONCORD DRUGS  LAURUS LABS   SHUKRA PHARMA  



Today's Market

Sensex Today Ends 456 Points Lower | IT Stocks Drag | 5 Reasons Why Indian Share Market is Falling Sensex Today Ends 456 Points Lower | IT Stocks Drag | 5 Reasons Why Indian Share Market is Falling(Closing)

After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.